

WEST Search History

DATE: Wednesday, October 23, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
	<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>		
L10	L4 and l1	2	L10
L9	L7 same (bone or osteo\$ or meyloma)	11	L9
L8	L7 same (bone or osteo\$)	11	L8
L7	L5 same (treat\$ or vivo or administer\$ or therap\$)	246	L7
L6	L5 same (treat or vivo or administer\$ or therap\$)	195	L6
L5	L4 with (anti or antibod\$)	376	L5
L4	((alpha.4.) or (alpha adj 4) or (alpha 4)or (vla adj 4) or vla 4 or vla-4)	5395	L4
L3	L2 and l1	6	L3
L2	yoneda-toshiyuki.in.	38	L2
L1	Mundy-gregory-\$.in.	42	L1

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 12:30:07 ON 23 OCT 2002)

INDEX '1MOBILITY, AGRICOLA, AQUASCI, BIOTECHNO, COMPENDEX, COMPUAB, CONF, CONFSCI, ELCOM, EVENTLINE, HEALSAFE, IMSDRUGCONF, ISMEC, LIFESCI, OCEAN, MEDICONF, PASCAL, PAPERCHEM2, POLLUAB, SOLIDSTATE, ADISALERTS, ADISINSIGHT, ADISNEWS, BIOSIS, CANCERLIT, ...' ENTERED AT 12:30:41 ON 23 OCT 2002

SEA (ALPHA 4 OR (ALPHA (A) 4) OR (ALPHA.4.) OR ALPHA4 OR (VLA (

1 FILE 1MOBILITY
844 FILE AGRICOLA
141 FILE AQUASCI
3799 FILE BIOTECHNO
307 FILE COMPENDEX
4 FILE COMPUAB
128 FILE CONFSCI
13 FILE ELCOM
7 FILE HEALSAFE
8 FILE ISMEC
2904 FILE LIFESCI
33 FILE OCEAN
1 FILE MEDICONF
5389 FILE PASCAL
101 FILE PAPERCHEM2
18 FILE POLLUAB
46 FILE SOLIDSTATE
117 FILE ADISALERTS
70 FILE ADISINSIGHT
10 FILE ADISNEWS
10110 FILE BIOSIS
2083 FILE CANCERLIT
21869 FILE CAPLUS
9 FILE CEN
666 FILE DDFB
847 FILE DDFU
2088 FILE DGENE
666 FILE DRUGB
40 FILE DRUGNL
1167 FILE DRUGU
118 FILE EMBAL
9411 FILE EMBASE
3538 FILE ESBIODBASE
2155 FILE IFIPAT
59 FILE IPA
734 FILE JICST-EPLUS
11 FILE KOSMET
8392 FILE MEDLINE
1031 FILE NAPRALERT
185 FILE NLDB
21 FILE PHARMAML
51 FILE PHIN
9049 FILE SCISEARCH
5348 FILE TOXCENTER
15808 FILE USPATFULL
135 FILE USPAT2
206 FILE ANABSTR
323 FILE BIOBUSINESS
19 FILE BIOCOMMERCE
392 FILE BIOTECHABS
392 FILE BIOTECHDS
1558 FILE CABA
73 FILE CEABA-VTB
49 FILE CIN
41 FILE CROPB

76 FILE CROPU
 61 FILE DRUGUPDATES
 139 FILE FEDRIP
 3 FILE FOREGE
 47 FILE FROSTI
 732 FILE FSTA
 2945 FILE GENBANK
 26 FILE NIOSHTIC
 86 FILE NTIS
 79 FILE PHAR
 239 FILE PROMT
 41 FILE SYNTHLINE
 8 FILE VETB
 21 FILE VETU
 1888 FILE WPIDS
 1888 FILE WPINDEX

L1 QUE (ALPHA 4 OR (ALPHA (A) 4) OR (ALPHA.4.) OR ALPHA4 OR (VLA (

FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, MEDLINE, PASCAL, TOXCENTER, BIOTECHNO, ESBIODBASE, GENBANK, LIFESCI, IFIPAT, DGENE, CANCERLIT, WPIDS, CABA, DRUGU, NAPRALERT, AGRICOLA, JICST-EPLUS, FSTA, DRUGB, BIOTECHDS, BIOBUSINESS, COMPENDEX, PROMT, ...' ENTERED AT 12:35:57 ON 23 OCT 2002

L2 5234 S L1 (S) (ANTI OR ANTIBOD?) (S) (TREAT? OR ADMINISTER? OR THERA
 L3 557 S L2 (S) (BONE OR OSTEO? OR MEYLOMA)
 L4 434 S L3 (S) ((MULTIPLE (A) MEYLOMA) OR (BONE (A) RESORPTION) OR
 L5 2080 S L1 (S) ((MULTIPLE (A) MEYLOMA) OR (BONE (A) RESORPTION) OR (B
 L6 132 DUP REM L4 (302 DUPLICATES REMOVED)

FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, IFIPAT, DGENE, CANCERLIT, WPIDS, CABA, DRUGU, BIOTECHDS, PROMT, NLDB, FEDRIP, ADISALERTS, ADISINSIGHT' ENTERED AT 13:14:30 ON 23 OCT 2002

L7 31 S L3 (S) ((MULTIPLE (A) MYELOMA) OR (BONE (A) RESORPTION))
 L8 14 DUP REM L7 (17 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 13:19:04 ON 23 OCT 2002

FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE, SCISEARCH, WPIDS, NLDB' ENTERED AT 13:27:10 ON 23 OCT 2002

E MUNDY GREGORY?/AU
 L9 353 S E1 OR E2
 E YONEDA TOSHIYUKI?/AU
 L10 156 S E2
 L11 75 S L9 AND L10
 L12 2 S L11 AND L6

WEST

Generate Collection

Print

39/943, 659

L5: Entry 1 of 2

File: PGPB

Apr 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020041874

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020041874 A1

TITLE: Methods of treating multiple myeloma and myeloma-induced bone resorption
using integrin antagonists

PUBLICATION-DATE: April 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mundy, Gregory R.	San Antonio	TX	US	
Yoneda, Toshiyuki	San Antonio	TX	US	

US-CL-CURRENT: 424/131.1; 424/133.1, 424/141.1, 424/178.1

CLAIMS:

1. A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.
2. The method of claim 1, wherein the antagonist is an .alpha.4 integrin binding agent.
3. The method of claim 1, wherein the antagonist is an .alpha.4 integrin ligand binding agent.
4. The method of claim 2, wherein the .alpha.4 integrin binding agent is selected from the group consisting of: a) an antibody homolog that antagonizes the interaction of both VLA-4 and .alpha.4.beta.7 with their respective .alpha.4 ligands; b) an antibody homolog that antagonizes the interaction of VLA-4 with its .alpha.4 ligand; and c) an antibody homolog that antagonizes the interaction of .alpha.4.beta.7 with its .alpha.4 ligand.
5. The method of claim 4, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.
6. The method of claim 3, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.
7. The method of claim 6, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.
8. The method of claim 1, wherein the antagonist is a small molecule.
9. The method of claim 1, wherein said antagonist is an antagonist of VLA-4.
10. The method of claim 8, wherein said small molecule is: 3BIO-8809.
11. The method of claim 1, wherein the composition is administered at a dosage so as

to provide from about 0.1 to about 20 mg/kg body weight.

12. A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a first composition comprising an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin, wherein said first composition is administered in combination with a therapeutically effective amount of a second composition comprising a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

13. The method of claim 12, wherein said compound is a chemotherapeutic agent.

14. The method of claim 13, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

15. The method of claim 14, wherein said chemotherapeutic agent is melphalan.

16. The method of claim 12, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said second composition than not administered in combination with said second composition; or a dosage of said compound is lower when administered in combination with said first composition than not administered in combination with said second composition, or both.

17. A method for inhibiting bone resorption associated with tumors of bone marrow, the method comprising administering to a mammal with said tumors an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin, in an amount effective to provide inhibition of said bone resorption.

18. The method of claim 17, wherein the antagonist is an .alpha.4 integrin binding agent.

19. The method of claim 17, wherein the antagonist is an .alpha.4 integrin ligand binding agent.

20. The method of claim 17, wherein the .alpha.4 integrin binding agent is an anti-VLA4 antibody homolog or anti-.alpha.4.beta.7 antibody homolog.

21. The method of claim 20, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

22. The method of claim 19, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.

23. The method of claim 22, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

24. The method of claim 17, wherein the antagonist is a small molecule.

25. The method of claim 17, wherein said antagonist is an antagonist of VLA-4.

26. The method of claim 24, wherein said small molecule is: 4BIO-8809.

27. The method of claim 17, wherein the antagonist is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg, based on the weight of the individual.

28. The method of claim 24, wherein the antagonist is administered in an amount effective to provide a dosage of small molecule of about 0.1-30 mg/kg body weight.

29. The method of claim 17, wherein said antagonist is administered in combination

with a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

30. The method of claim 29, wherein said compound is a chemotherapeutic agent.

31. The method of claim 30, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

32. The method of claim 30, wherein said chemotherapeutic agent is melphalan.

33. The method of claim 29, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said compound than not administered in combination with said compound; or a dosage of said compound is lower when administered in combination with said antagonist than not administered in combination with said antagonist, or both.

34. A method of treating a subject having a disorder characterized by the presence of osteoclastogenesis, the method comprising administering to the subject an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit bearing integrin, in an amount sufficient to suppress the osteoclastogenesis.

35. The method of claim 34, wherein the antagonist is an .alpha.4 integrin binding agent.

36. The method of claim 34, wherein the antagonist is an .alpha.4 integrin ligand binding agent.

37. The method of claim 35, wherein the .alpha.4 integrin binding agent is an anti-VLA4 antibody homolog or an anti-.alpha.4.beta.7 binding agent.

38. The method of claim 36, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

39. The method of claim 36, wherein the .alpha.4 integrin ligand binding agent is an anti-VCAM-1 antibody homolog.

40. The method of claim 39, wherein the antibody homolog is selected from the group consisting of a human antibody, a chimeric antibody, a humanized antibody and fragments thereof.

41. The method of claim 34 wherein the antagonist is a small molecule.

42. The method of claim 41, wherein said antagonist is an antagonist of VLA-4.

43. The method of claim 41, wherein said small molecule is: 5BIO-8809.

44. The method of claim 34, wherein the antagonist is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg body weight.

45. The method of claim 41, wherein the antagonist is administered in an amount effective to provide a dosage of small molecule of about 0.1-20 mg/kg body weight.


46. The method of claim 34, wherein said antagonist is administered in combination with a compound that is not an antagonist of an interaction between an .alpha.4 subunit-bearing integrin and a ligand for an .alpha.4 subunit-bearing integrin.

47. The method of claim 46, wherein said compound is a chemotherapeutic agent.

48. The method of claim 47, wherein said chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, thalidomide, erythropoietin, an antagonist of IL6 and an antagonist of IL15.

49. The method of claim 47, wherein said chemotherapeutic agent is melphalan.

50. The method of claim 46, wherein, to be therapeutically effective, a dosage of said antagonist is lower when administered in combination with said compound than not administered in combination with said compound; or a dosage of said compound is lower when administered in combination with said antagonist than not administered in combination with said antagonist, or both.



PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search PubMed	for HP2/4 and alpha4						Preview	Go
Clear								

Limits Preview/Index History Clipboard Details

- Search History will be lost after one hour of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Search	Most Recent Queries	Time	Result
#28	Search HP2/4 and alpha4	13:30:04	<u>2</u>
#27	Search HP2/4 and alpha 4	13:29:58	<u>0</u>
#25	Search ellis and barber and 925	13:20:48	<u>1</u>
#23	Search hp2/4 antibodies and alpha4	13:12:19	<u>2</u>
#22	Search hp2/4 antibodies and alpha 4	13:12:10	<u>0</u>
#19	Search p4c2 antibodies and alpha 4	12:35:28	<u>3</u>
#18	Search p4c2 antibodies and alpha4	12:35:25	<u>0</u>
#14	Search L25 and alpha 4 and antibody	12:29:55	<u>6</u>
#13	Search L25 and alpha 4	12:29:36	<u>11</u>
#9	Search L25 and alpha4	12:28:03	<u>3</u>
#8	Search L25 and myeloma	12:27:51	<u>0</u>
#7	Search l25 and myeloma	12:27:43	<u>0</u>
#5	Search hp antibodies and alpha4	12:08:26	<u>2</u>
#4	Search hp antibodies	12:08:08	<u>644</u>
#3	Search hp 1/2 antibodies	12:07:57	<u>0</u>
#2	Search hp1/2 antibodies	12:07:51	<u>0</u>

Clear History

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)